We recently published a list of 10 Top Insider Stock Buys And Sells In January. In this article, we are going to take a look ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

However, the FDA recently placed a black-box warning on metoclopramide because of the risk of related side effects, including tardive dyskinesia, the incidence of which has been cited to be as ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday. A ...

It is also used to treat tardive dyskinesia, another form of movement disorder. Sales were $638 million last year and according to Teva will approach the $1 billion mark in 2021, despite the ...

State of Alaska Department of Revenue cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the ...

The federal health insurance program has selected 15 additional drugs covered by Medicare Part D for its next round of price ...

Tardive dyskinesia is primarily associated with the use of certain medications, particularly antipsychotic medications used to treat conditions like schizophrenia, bipolar disorder, and other ...